Articles related to HEALTH OUTCOMES

The authors evaluated the treatment approaches and outcomes of 110 patients with primary plasma cell leukemia (pPCL) in this retrospective study . Higher complete response rates were associated with treatment with bortezomib, lenalidomide, and dexamethasone (VRd) or daratumumab-based quadruplets (DBQ) and autologous stem-cell transplantation. Patients who received VRd/DBQ had better outcomes than those who received other bortezomib-based combinations or standard chemotherapy.

According to the findings of this study, patients with rectal cancer who were monitored using a watch-and-wait approach had a good quality of life, with some patients reporting bowel and sexual dysfunction. When patients needed surgery, their quality of life and functional outcome deteriorated. These findings will be useful in daily practice to advise patients on what to expect from a wait-and-see approach.

A total of 1,643 men with localized prostate cancer were enrolled in a trial to assess treatment efficacy, with 545 randomly assigned to active monitoring, 553 to prostatectomy, and 545 to radiotherapy. Prostate cancer-specific mortality was low after 15 years of follow-up, regardless of treatment. Thus, deciding on therapy entails weighing the benefits and drawbacks of treatments for localized prostate cancer.

Lumateperone 42 mg/d is effective in the treatment of schizophrenia and has no clinically significant effects on body weight, metabolic variables, motor function, the ECG QT interval, or prolactin levels, with a likelihood to be helped or harmed (LHH) much greater than 1 when comparing therapeutic response to these tolerability/safety outcomes. When comparing therapeutic response versus a somnolence/sedation AE, lumateperone appears to be associated with somnolence/sedation, and LHH approaches 1. In indirect comparisons with other antipsychotics, this somnolence/sedation AE profile is not dissimilar; however, the absence of weight gain, glucose/lipid abnormalities, and akathisia, as well as the absence of prolactin elevations, distinguishes lumateperone.

Mike Serbinis, CEO of League; Pete Anevski, CEO of Progyny; John Erwin, CEO of Carenet Health; Mick Mazour, president of Carenet Health; BJ Schaknowski, CEO of symplr; Tanja Dowe, CEO of the Debiopharm Innovation Fund; Derek Streat, Co-founder and CEO of DexCare; and Kimberly O’Loughlin, CEO of Health Recovery Solutions, provide their thoughts on this year’s meeting, with value-based care, healthcare technology, hospital medicine, and the overall economy being the familiar strings.

Healthgrades communicates performance in two ways—through ratings and awards—to assist consumers in evaluating and comparing hospital performance specific to specialist service lines and speciality emphasis areas. Using Medicare inpatient data from the Medicare Provider Analysis and Review (MedPAR) file purchased from the Centers for Medicare and Medicaid Services (CMS) for the years 2019 through 2021, hospitals were evaluated for overall clinical excellence and measure performance. Data on patient outcomes for 31 diseases or treatments were examined for almost all hospitals in the nation. Also, with the fewest occurrences of 14 avoidable patient safety events, hospitals in the top 10% of the country are honored with the Patient Safety Excellence Award, and analyzing data from surveys of the hospital’s own patients to evaluate patient experience across 10 metrics, the top 15% of hospitals receive the Outstanding Patient Experience Award. Finally, each year, Healthgrades recognizes hospitals in the United States that offer the most common gynecologic treatments and where patients are at a decreased risk of complications during their stay for labor and delivery.